Natalizumab
CAS No. 189261-10-7
Natalizumab( —— )
Catalog No. M23864 CAS No. 189261-10-7
Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 218 | In Stock |
|
| 5MG | 392 | In Stock |
|
| 10MG | 629 | In Stock |
|
| 25MG | 938 | In Stock |
|
| 50MG | 1237 | In Stock |
|
| 100MG | 1665 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNatalizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionNatalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
-
DescriptionNatalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
Recptorα4β1 integrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number189261-10-7
-
Formula Weight——
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
BMS-688521
BMS-688521 BMS-688521 is an orally active and potent inhibitor of LFA-1/ICAM interaction, a small molecule antagonist of leukocyte function-associated antigen-1 (LFA-1), with potential anti-inflammatory activity.
-
Lifitegrast sodium
Lifitegrast sodium (SAR-1118-023 sodium) is a small molecule integrin antagonist that inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), which reduces inflammation of the ocular surface, and may be used in the study of dry eye.
-
LLP2A
LLP2A is a high-affinity, selective peptidomimetic ligand of α4β1 integrin with IC50 of 2 pM.
Cart
sales@molnova.com